An in-vitro study on the metabolism of rokitamycin and possible interactions of the drug with rat liver microsomes

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 10, 1999, Pages 1167-1174

  Zhao, Xue Jun ^a   Ishizaki, Takashi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; CHOLINESTERASE; CIMETIDINE; CYTOCHROME P450 REDUCTASE; ESTERASE; ESTERASE INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; KITASAMYCIN; MEQUITAZINE; METRIFONATE; PHYSOSTIGMINE; QUININE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROKITAMYCIN; TERFENADINE; THEOPHYLLINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHLORPHENIRAMINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MACROLIDES; MICROSOMES, LIVER; MIOCAMYCIN; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; THEOPHYLLINE;

EID: 0032708513     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991776705     Document Type: Article

References (35)

1. Amsden, G. W. (1995) Macrolides versus alalides: a drug-interaction update. Ann. Pharmacother. 52: 906-917
2. Cazzola, M., Matera, M. G., Paterno, E., Scaglione, F., Santangelo, G., Rossi, F. (1991) Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. J. Chemother. 3: 240-244
3. Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T., Ishizaki, T. (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266: 52-59
4. Echizen, H., Kawasaki, H., Chiba, K., Tani, M., Ishizaki, T. (1993) A potent inhibition effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J. Pharmacol. Exp. Ther. 264: 1425-1431
5. Goto, S., Tsuji, A., Ogawa, M., Yokoyama, S., Sagai, H., Toriya, M., Morohoshi, T., Hayano, K. (1984) Bacteriological evaluations of the metabolites of TMS-19-Q, a new macrolide antibiotic. Chemotherapy 32 (Suppl. 6): 37-45
6. Guengerich, F. P. (1994) Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol. Lett. 70: 133-138
7. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype of genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060
8. Hallak, M., Giacobini, E. (1987) A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 26: 521-530
9. Iatsimirskaia, E., Tulebaev, S., Storozhuk, E., Utkin, I., Smith, D., Gerber, N., Koudriakova, T. (1997) Metabolism of rifabutin in human enterocyte and liver microsomes, and drug interactions with macrolides and antifungal agents. Clin. Pharmacol. Ther. 61: 554-562
10. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275
11. Marre, F., de Sousa, G., Roloff, A. M., Rahmani, R. (1993) In vitro interaction between cyclosporin and macrolide antibiotics. Br. J. Clin. Pharmacol. 35: 447-448
12. Morishita, M., Ohno, M., Serizawa, K., Fujiwara, T., Sakakibara, H. (1984a) Isolation and identification of metabolites of TMS-19-Q. Chemotherapy 32 (Suppl. 6): 85-92
13. Morishita, M., Suzuki, T., Sakai, A., Endo, S., Watanabe, M., Nagata, A., Ishioka, T. (1984b) Studies on absorption, metabolism and excretion of TMS-19-Q in humans. Chemotherapy 32 (Suppl. 6): 99-115
14. Morishita, M., Suzuki, T., Hayano, K. (1987) The in vivo pharmacokinetics of rokitamycin: a new macrolide antibiotic. Chemother. Field 3: 381-390
15. 5). Chemotherapy 32 (Suppl. 6): 12-25
16. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., Nebert, D. W. (1996) P450 superfamily: update on new sequence, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42
17. 1-receptor antagonists (the antihistamines). Clin. Pharmacokinet. 10: 477-497
18. Penston, J. G., McColl, K. E. L. (1997) Eradication of Helicobacter pylori: an objective assessment of current therapies. Br. J. Clin. Pharmacol. 43: 223-243
19. Periti, P., Mazzei, T., Mini, E., Novelli, A. (1992) Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23: 106-131
20. Rodrigues, A. D., Roberts, E. M., Mulford, D. J., Yao, Y., Ouellet, D. (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos. 25: 623-630
21. Rossi, M., Markovitz, S., Callahan, T. (1987) Defining the active site of cytochrome P-450: the crystal and molecular structure of an inhibitor, SKF-525A. Carcinogenesis 8: 881-887
22. 14C-rokitamycin: absorption, distribution, metabolism and excretion in infant rats. Jpn J. Antibiot. 41: 797-808
23. Somogyi, A., Muirhead, M. (1987) Pharmacokinetic interaction of cimetidine. Clin. Pharmacokinet. 12: 321-366
24. Sorkin, E. M., Heel, R. C. (1985) Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 34-56
25. 14C-rokitamycin. IV. Absorption, metabolism and excretion in dogs. Jpn J. Antibiot. 40: 539-552
26. 14C-rokitamycin. I. Absorption, distribution, metabolism and excretion in rats. Jpn J. Antibiot. 40: 499-518
27. Tsuruta, S., Nakamura, K., Arimori, K., Nakano, M. (1997) Effects of erythromycin, clarithromycin and rokitamycin on nifedipine metabolism in rats. Biol. Pharm. Bull. 20:411-416
28. Tunek, A., Svensson, L.-Å. (1988) Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. Drug Metab. Dispos. 16: 759-764
29. von Rosensteil, N.-A., Adam, D. (1995) Macrolide antibacterials; drug interactions of clinical significance. Drug Safety 13: 105-122
30. Walsh, J. H., Peterson, W. L. (1995) The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333: 984-991
31. Wanwimolruk, S., Wong, S. M., Zhang, H., Coville, P. F. (1996) Simultaneous determination of quinine and a major metabolite 3-hydroxyquinine in biological fluids by HPLC without extraction. J. Liq. Chromatogr. 19: 293-305
32. Williams, F. M. (1985) Clinical significance of esterases in man. Clin. Pharmacokinet. 10: 392-403
33. Yamaoka, K., Tanigawara, Y., Nakagawa, T., Uno, J. (1981) A pharmacokinetic analysis programme (MULTI) for microcomputer. J. Pharmacobiodyn. 4: 879-885
34. Zhao, X.-J., Ishizaki, T. (1997) The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. J. Pharmacol. Exp. Ther. 283: 1168-1176
35. Zhao, X.-J., Koyama, E., Ishizaki, T. (1999) An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab. Dispos. 27: 776-785